Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer

Multiple randomized studies have shown that combination of chemotherapy and immune checkpoint inhibitors (ICIs) leads to better response rates and survival as compared to chemotherapy alone in the advanced stage of NSCLC. Data suggesting a benefit to using ICIs in the neoadjuvant therapy of patients...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancer Med
Glavni autori: Tfayli, Arafat, Al Assaad, Majd, Fakhri, Ghina, Akel, Reem, Atwi, Hanine, Ghanem, Hady, El Karak, Fadi, Farhat, Fadi, Al Rabi, Kamal, Sfeir, Pierre, Youssef, Pierre, Mansour, Ziad, Assi, Hazem, Haidar, Mohamad, Abi Ghanem, Alain, Khalifeh, Ibrahim, Boulos, Fouad, Mahfouz, Ramy, Youssef, Bassem, Zeidan, Youssef, Bejjany, Rachelle, Khuri, Fadlo
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2020
Teme:
Clinical Cancer Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7666740/
https://ncbi.nlm.nih.gov/pubmed/32991781
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3456
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items